US-based medical device firm Cardiovascular Systems (CSI) has received CE Mark for its Stealth 360º Orbital Atherectomy System (OAS), which is indicated to treat patients who suffer from peripheral arterial disease (PAD), a common circulatory disease.

In PAD, plaque deposits build up on the walls of blood vessels, reducing blood flow.

The company said that Stealth 360º will be available in Europe with a 0.014in guide wire platform, and crown sizes of 1.25mm, 1.50mm, 1.75mm and 2mm.

The system’s main components include orbital atherectomy device, saline pump, atherectomy guide wire and atherectomy lubricant.

"Our technology, with its unique mechanism of action, demonstrated it can safely and effectively treat this complex disease, with lasting results."

CSI president David Martin said: "Securing CE Mark for Stealth 360º greatly expands our market opportunity and is an important milestone toward benefiting patients in Europe suffering from PAD, especially those with critical limb ischemia, (CLI) who have been underserved by other treatment options.

"A determining factor for CLI is calcium buildup in leg arteries, particularly small vessels below the knee.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Our technology, with its unique mechanism of action, demonstrated it can safely and effectively treat this complex disease, with lasting results.

"We are excited to be able to offer our OAS technology as a solution to millions of PAD sufferers outside of the US and are currently evaluating the timing and structure of our plans to commercialize our products in Europe."

On average, 27 million individuals suffer from PAD in Europe and North America, and CLI a chronic, severe form of PAD affects 2.7 million people in North America and 3.3 million in Western Europe.

The company is focused on developing and commercialising new solutions for treating vascular and coronary disease.